Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY<sup>®</sup>) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study.

Jones, Aksana; Cohen-Barak, Orit; Radivojevic, Andrijana; Fiedler-Kelly, Jill

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study.

Jones, Aksana; Cohen-Barak, Orit; Radivojevic, Andrijana; Fiedler-Kelly, Jill.

Afiliação

Jones A; Cognigen Corporation, Buffalo, NY 14221, USA.
Cohen-Barak O; Teva Pharmaceutical Industries, Netanya 4250483, Israel.
Radivojevic A; IntiGrowth LLC, New York, NY 10025, USA.
Fiedler-Kelly J; Cognigen Corporation, Buffalo, NY 14221, USA.

Pharmaceutics ; 13(6)2021 May 24.

Article em En | MEDLINE | ID: mdl-34074002

Palavras-chave

fremanezumab; pediatric dose selection; pediatric migraine; pharmacometrics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceutics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google